Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis
Authors
Keywords
-
Journal
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-11-10
DOI
10.1016/j.jaci.2021.11.001
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID‐19
- (2020) Sarah C.J. Jorgensen et al. PHARMACOTHERAPY
- Inborn errors of type I IFN immunity in patients with life-threatening COVID-19
- (2020) Qian Zhang et al. SCIENCE
- Modulation of inflammatory gene transcripts in psoriasis vulgaris: Differences between ustekinumab and etanercept
- (2019) Carrie Brodmerkel et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Loss of the interleukin-6 receptor causes immunodeficiency, atopy, and abnormal inflammatory responses
- (2019) Sarah Spencer et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain
- (2019) James R. Burke et al. Science Translational Medicine
- The CCL20 and CCR6 axis in psoriasis
- (2019) Kazuhisa Furue et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis
- (2018) Curdin Conrad et al. Nature Communications
- Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment
- (2018) Josef S. Smolen et al. JOURNAL OF RHEUMATOLOGY
- Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis
- (2018) Kim Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interleukin-22 and Its Correlation with Disease Activity in Plaque Psoriasis
- (2018) Bartłomiej Wawrzycki et al. ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS
- Psoriatic skin molecular and histopathological profiles following treatment with risankizumab versus ustekinumab
- (2018) Sudha Visvanathan et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Evaluation of the Short‐, Mid‐, and Long‐term Effects of Tofacitinib on Lymphocytes in Patients with Rheumatoid Arthritis
- (2018) Ronald van Vollenhoven et al. Arthritis & Rheumatology
- Psoriasis pathogenesis and the development of novel targeted immune therapies
- (2017) Jason E. Hawkes et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis
- (2017) Robert Wolk et al. Journal of Clinical Lipidology
- The role of IL-23 and the IL-23/TH 17 immune axis in the pathogenesis and treatment of psoriasis
- (2017) G. Girolomoni et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- The emerging safety profile of JAK inhibitors in rheumatic disease
- (2017) Kevin L. Winthrop Nature Reviews Rheumatology
- The role of IL-6 in host defence against infections: immunobiology and clinical implications
- (2017) Stefan Rose-John et al. Nature Reviews Rheumatology
- Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials
- (2017) Frédéric Vanhoutte et al. Arthritis & Rheumatology
- A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis
- (2016) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- JAK1-STAT3 blockade by JAK inhibitor SHR0302 attenuates inflammatory responses of adjuvant-induced arthritis rats and decreases Th17 and total B cells
- (2016) Huaxun Wu et al. JOINT BONE SPINE
- Effects of Di-(2-ethylhexyl) Phthalate on Lipid Metabolism by the JAK/STAT Pathway in Rats
- (2016) Yiyang Jia et al. International Journal of Environmental Research and Public Health
- Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
- (2016) Mark C. Genovese et al. Arthritis & Rheumatology
- Human Dendritic Cells Mitigate NK-Cell Dysfunction Mediated by Nonselective JAK1/2 Blockade
- (2016) Shane A. Curran et al. Cancer Immunology Research
- Meta-analysis derived atopic dermatitis (MADAD) transcriptome defines a robust AD signature highlighting the involvement of atherosclerosis and lipid metabolism pathways
- (2015) David A. Ewald et al. BMC Medical Genomics
- Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome
- (2015) Alexandra Y. Kreins et al. JOURNAL OF EXPERIMENTAL MEDICINE
- IL-36γ (IL-1F9) Is a Biomarker for Psoriasis Skin Lesions
- (2015) Angelo Massimiliano D'Erme et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis
- (2015) Mark C. Genovese et al. Arthritis & Rheumatology
- Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis
- (2014) Howard Sofen et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Molecular profiling of contact dermatitis skin identifies allergen-dependent differences in immune response
- (2014) Nikhil Dhingra et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers
- (2014) Jack G. Shi et al. JOURNAL OF CLINICAL PHARMACOLOGY
- IL-19 Is a Component of the Pathogenetic IL-23/IL-17 Cascade in Psoriasis
- (2014) Ellen Witte et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Disruption of JAK2 in Adipocytes Impairs Lipolysis and Improves Fatty Liver in Mice With Elevated GH
- (2013) Sarah M. Nordstrom et al. MOLECULAR ENDOCRINOLOGY
- Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis
- (2013) John D Isaacs et al. ARTHRITIS RESEARCH & THERAPY
- Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study
- (2012) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis
- (2012) James G. Krueger et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone
- (2011) Joel M. Kremer et al. ARTHRITIS AND RHEUMATISM
- Inter-Regulation of Th17 Cytokines and the IL-36 Cytokines In Vitro and In Vivo: Implications in Psoriasis Pathogenesis
- (2011) Yijun Carrier et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Assessment of the Psoriatic Transcriptome in a Large Sample: Additional Regulated Genes and Comparisons with In Vitro Models
- (2010) Johann E. Gudjonsson et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Integrative Responses to IL-17 and TNF-α in Human Keratinocytes Account for Key Inflammatory Pathogenic Circuits in Psoriasis
- (2010) Andrea Chiricozzi et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Evaluation of the Psoriasis Transcriptome across Different Studies by Gene Set Enrichment Analysis (GSEA)
- (2010) Mayte Suárez-Fariñas et al. PLoS One
- Janus kinases in immune cell signaling
- (2009) Kamran Ghoreschi et al. IMMUNOLOGICAL REVIEWS
- Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes
- (2009) Lisa C. Zaba et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- The IL-23/Th17 Axis in the Immunopathogenesis of Psoriasis
- (2009) Antonella Di Cesare et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
- (2009) David A. Barbie et al. NATURE
- Psoriasis
- (2009) Frank O. Nestle et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Effect of the JAK Inhibitor CP-690,550 on Peripheral Immune Parameters in Stable Kidney Allograft Patients
- (2009) Evelien A. F. J. van Gurp et al. TRANSPLANTATION
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started